SWM
SGMO

SeaCrest Wealth Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

SeaCrest Wealth Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$2K – 2275
2018
Q3 		$2K Buy
+100
New +$1.52K ﹤0.01% 2084
2018
Q1 		– Sell
-300
Closed -$5K – 2275
2017
Q4 		$5K Buy
+300
New +$4.46K ﹤0.01% 1819

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SeaCrest Wealth Management's SGMO Position: Q4 2018 in Review

SeaCrest Wealth Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2018, closing a stake of 100 shares — an estimated $2K sold.

SeaCrest Wealth Management first reported a position in SGMO in Q4 2017 and held it in 2 quarters. The position peaked at $5K in Q4 2017. 197 funds tracked by Wall St. Rank hold SGMO as of Q4 2018.

  • SeaCrest Wealth Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2018 after selling out during the quarter.
  • SeaCrest Wealth Management sold 100 SANGAMO THERAPEUTICS INC shares in Q4 2018, an estimated $2K.
  • SeaCrest Wealth Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2017 and held it in 2 quarters.
  • SeaCrest Wealth Management's SANGAMO THERAPEUTICS INC position peaked at $5K in Q4 2017.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2018.

Based on SeaCrest Wealth Management's 13F filing for Q4 2018, filed 13 Feb 2019.